Principal Scientist

The case was approved based on 5 peer-reviewed journal articles in high-impact venues like Nature, Cell, and Science, which amassed 1,359 citations from researchers in over 50 countries. The petitioner also demonstrated significant judging experience with 13 peer reviews and an editorial board position. These metrics satisfied the criteria for original contributions of major significance, scholarly authorship, and judging the work of others.

The petition was approved based on the satisfaction of at least three EB-1A criteria, including scholarly articles, judging, and original contributions of major significance. Specific metrics included 8 peer-reviewed journal articles, 904 citations, and 15 peer review assignments for influential AI and computational venues. The case was strengthened by evidence of competitive funding from the Bill & Melinda Gates Foundation and Roche GmbH.

The petition was approved based on the petitioner's 47 peer-reviewed publications in top-tier journals and a high citation count of 2,811. Additionally, her 48 journal reviews served as evidence of her judging the work of others. These metrics satisfied the EB-1A criteria for scholarly articles, original contributions, and judging roles.

The petition was approved based on the petitioner's significant contributions to cancer immunotherapy, including 9 peer-reviewed scientific articles and 554 citations. She demonstrated her authority through 2 peer-review judging invitations and the filing of 1 patent and 2 patent applications. The case satisfied EB-1A criteria by showing her work is widely recognized and relied upon by researchers in at least 49 countries.